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Case Report
Benign recurrent intrahepatic cholestasis:
report of two local cases
Abstract
Benign Recurrent Intrahepatic Cholestasis (BRIC) is a rare 
disorder characterized by recurrent episodes of cholestasis 
without permanent liver damage. Familial and sporadic cases 
have been reported and both autosomal recessive and autosomal 
dominant inheritance described. We report two children with 
BRIC without any previous family history.
Introduction 
Cholestatic syndromes are inborn or acquired disorders of 
bile formation and transport.1  Benign intrahepatic cholestasis 
(BRIC) and progressive familial intrahepatic cholestasis (PFIC) 
are two inherited cholestatic syndromes characterized at 
molecular level in recent years.  Clinical differentiation of the two 
syndromes may be difficult but is essential as patients with PFIC 
will progress to liver cirrhosis and require liver transplantation 
later on in life while the natural history of patients with BRIC 
is benign. Only recently was it recognized that BRIC, which 
was previously believed to be a milder form of PFIC1, might be 
caused by more than one gene mutation. Both syndromes are 
rare and characterized by recurrent episodes of intense pruritus, 
hyperbilirubinaemia and steatorrhoea. Attacks last from several 
weeks to months and resolve spontaneously. Between attacks 
patients remain well for months to years.2   Biochemical analysis 
reveals elevation of alkaline phosphatase levels and markedly 
raised serum bilirubin. Gamma glutamyl transferase (GGT) 
concentrations are normal or slightly elevated with levels 
returning to normal after the attack subsides.
Treatment is usually symptomatic and limited to relief of 
pruritus.  The use of specific drugs such as ursodeoxycholic acid 
and cholestyramine is questionable. The long-term prognosis 
for BRIC patients is good and both our patients are thriving 
and otherwise well.
Case 
VA is the first child of healthy unrelated parents.  She 
presented at the age of one year two months with increasing 
jaundice, dark urine and pruritus.  She continued to have 
recurrent episodes of jaundice and pruritus with variable 
intervals between episodes, approximately every year and lasting 
about three weeks.  Between episodes the child was completely 
asymptomatic.  In total she had around seven episodes of 
jaundice and was hospitalised only once at presentation.   There 
is no history of liver disease in the family.
On examination during episodes the child was icteric 
without pallor.  She had obvious scratch marks and mild 
hepatomegaly.  Otherwise the examination was completely 
normal. Liver function tests carried out during these episodes 
showed conjugated hyperbilirubinaemia with bilirubin level 
ranging from 185-358 μmol/l (direct bilirubin fraction in the 
range of 130-181 μmol/l) with a high alkaline phosphatase 
level (range 466-768 IU/l).  Other liver enzymes including 
alanine transaminase, aspartate transaminase and gamma 
glutamyl transferases were within normal limits. Serum protein, 
albumin and prothrombin time were always normal and serum 
caeruloplasmin was also within normal limits. Treatment has 
always been limited to symptomatic relief of pruritus only, and 
spontaneous improvement has usually occurred within 3 weeks, 
with complete normalisation of serum bilirubin and alkaline 
phosphatase concentrations. The child is thriving well and being 
followed up at our outpatient’s clinic. DNA analysis has been 
requested to identify further and results are pending.
Case 2
MB was born at term following a normal pregnancy and 
delivery.  He had no history of any significant childhood 
illnesses.  He is the only child of healthy unrelated parents with 
no family history of liver disease. 
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He first presented at the age of 10 months with mild jaundice 
and pruritus.  His second episode of jaundice was at 18 months 
of age with severe pruritus, pale stools and dark urine.    These 
exacerbations of jaundice recurred approximately every year 
since then, lasting about one to one and a half months.
During episodes the child appeared jaundiced and had 
multiple scratch marks but was otherwise normal. Blood 
investigations performed at that time showed a conjugated 
hyperbilirubinaemia with a bilirubin level of 138μmol/l 
(direct fraction of 76μmol/l) and an alkaline phosphatase 
level of 1387IU/l.   These investigations normalized when the 
symptoms resolved. Alpha-1-antitrypsin, serum haptoglobin 
level, caeruloplasmin level and other liver function tests were 
all normal.  An ultrasound of the liver was also normal. 
A liver biopsy was performed at 18 months of age and 
showed mild portal changes and almost no inflammation.  Pure 
cholestasis was seen with distinct bile lakes and these features 
together with the clinical picture were consistent with BRIC. 
To date MB remains well and has exacerbations of jaundice, 
steatorrhoea and pruritus almost yearly.
Discussion
Summerskill and Walshe first described benign recurrent 
intrahepatic cholestasis in 19593,4  as recurrent episodes of 
jaundice and pruritus. It is now recognized as BRIC, is a 
syndrome due to a mutation in ATP8B1, an aminophospholipid 
transporter, while BRIC2 is caused by a mutation in ABCB11. 
There are at least three forms of BRIC all with a similar phenotype. 
BRIC types 1 and 2 are inherited as autosomal recessive and are 
related to mutations on chromosomes 18 and 2 respectively. 
BRIC type 3 is transmitted as an autosomal dominant disease 
and is not linked to mutations on chromosomes 18 or 2.5 The 
hallmark of the disease is cholestasis. Patients present with 
recurrent bouts of jaundice and cholestasis lasting from two 
to twenty four weeks.  Typically the disease manifests early in 
life but later presentations have been reported.6  Pruritus is a 
prominent symptom in BRIC patients and usually occurs early 
on during exacerbations sometimes before the appearance of 
jaundice.
Biochemical findings consist of elevated total and direct 
bilirubin, raised alkaline phosphatase levels and elevated bile 
salts but normal gamma glutamyl transferase levels.
Elevation of alanine aminotransferase (AST) and aspartate 
aminotransferase levels (ALT) levels may occur but this 
is usually mild to moderate and levels return to normal 
following resolution of the exacerbation.6  Ultrasonographic 
examination of the liver, gallbladder and bile ducts is normal and 
cholangiography does not reveal any abnormalities. Histological 
findings on liver biopsy reveal accumulation of bile plugs in the 
bile canaliculi.7  Often the diagnosis in BRIC patients is made 
very late and patients are subjected to invasive investigations. 
Elevation in gamma glutamyl transferase levels or rising levels 
of ALT and AST should suggest an alternative diagnosis of 
progressive familial intrahepatic cholestasis (PFIC).
Treatment of the condition is purely symptomatic and 
aimed mainly at the relief of pruritus. Reports of the benefits 
of cholestyramime and ursodeoxycholic acid are conflicting6 
and the use of rifampicin has been recently shown to 
shorten the duration of cholestasis.8  Both our patients were 
prescribed ursodeoxycholic acid for the latest exacerbation 
and both reported an improvement in pruritus and duration 
of exacerbation.
They have been followed up for three and eight years 
respectively and continue to have intermittent attacks of 
cholestasis. 
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